Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10351315 | 0.98 | AOC3 (0.40) | PTPN1AOC3DPP4SMN1; SMN2KDM4E | |
| SCHEMBL34462997 | 0.80 | TAAR1 (0.49) | SMN1; SMN2KDM4ETAAR1HTR2A | |
| SCHEMBL29617909 | 0.78 | PTPN1 (0.42) | PTPN1SMN1; SMN2KDM4ECHEK1AURKA | |
| SCHEMBL3934756 | 0.78 | AOC3 (0.61) | AOC3DPP4KDM4EHTR2AALDH1A1 | |
| SCHEMBL113737 | 0.78 | CA1 (0.50) | DPP4SMN1; SMN2KDM4ETAAR1ALDH1A1 | |
| SCHEMBL16274742 | 0.78 | TAAR1 (0.46) | PTPN1AOC3DPP4SMN1; SMN2KDM4E | |
| SCHEMBL27885726 | 0.77 | SMN1; SMN2 (0.44) | DPP4SMN1; SMN2KDM4ETAAR1ALDH1A1 | |
| SCHEMBL31151088 | 0.77 | PTPN1 (0.43) | PTPN1SMN1; SMN2TAAR1HTR2A | |
| SCHEMBL30741239 | 0.77 | CA12 (0.48) | PTPN1SMN1; SMN2KDM4EJAK2EGFR | |
| SCHEMBL30741241 | 0.77 | CA12 (0.48) | PTPN1SMN1; SMN2KDM4EJAK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4888283-A | Selective inhibitors of benzylaminoxidases with respect to other aminoxidases | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1989-12-19 | — | — | US | claimed |
| EP-1608365-B1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | R TECH UENO LTD (JP) | 2013-10-02 | — | — | EP | disclosed |
| EP-1786792-B1 | THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY | ASTELLAS PHARMA INC (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-7442715-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2008-10-28 | — | — | US | disclosed |
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2008-05-22 | — | — | US | disclosed |
| US-20080015202-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | ASTELLAS PHARMA INC. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20070254931-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | ASTELLAS PHARMA INC. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1791835-A2 | THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY | Astellas Pharma Inc. (JP) | 2007-06-06 | — | — | EP | disclosed |
| US-20060276521-A1 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-12-07 | — | — | US | disclosed |
| US-7125901-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-10-24 | — | — | US | disclosed |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-10-12 | — | — | US | disclosed |
| US-20060128770-A1 | Thiazole derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2006-06-15 | — | — | US | disclosed |
| WO-2006028269-A2 | THIAZOLE DERIVATIVES HAVING VAP-1 IHIBITORY ACTIVITY | ASTELLAS PHARMA INC. (JP) | 2006-03-16 | — | — | WO | disclosed |
| US-20040259923-A1 | Compound useful as cellular adhesion protein and as antiedemic agent | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-0210140-B1 | INHIBITORS OF BENZYLAMINOXIDASES, SELECTIVE WITH RESPECT TO OTHER AMINOXIDASES | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1990-06-13 | — | — | EP | disclosed |
| US-4888283-A | Selective inhibitors of benzylaminoxidases with respect to other aminoxidases | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1989-12-19 | — | — | US | disclosed |
| EP-0210140-A2 | Inhibitors of benzylaminoxidases, selective with respect to other aminoxidases | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1987-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | VCAM1, ICAM1, VAPB | PTPN1 2962/4885AOC3 202/4885DPP4 1812/4885 |
| US-20060276521-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | PTPN1 530/4885AOC3 782/4885DPP4 2729/4885 |
| US-20080015202-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | VCAM1, VAPB, VAPA | PTPN1 2040/4885AOC3 163/4885DPP4 4556/4885 |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | VCAM1, VAPB, ICAM1 | PTPN1 2760/4885AOC3 85/4885DPP4 1145/4885 |
| US-20070254931-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | VCAM1, VAPB, VAPA | PTPN1 651/4885AOC3 386/4885DPP4 1132/4885 |
| US-20060128770-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | PTPN1 530/4885AOC3 782/4885DPP4 2729/4885 |
| US-20040259923-A1 | Compound useful as cellular adhesion protein and as antiedemic agent | VCAM1, ICAM1, VAPB | PTPN1 1362/4885AOC3 590/4885DPP4 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.